Agilent Technologies, Inc. (A) Stock Analysis
Is A a good investment?
Agilent Technologies, Inc. (A) has a Plutrex AI rating of 58.0/100 as of August 20, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Profitability fortress with operating margin 23.7% (+105.6% vs. industry 11.5%), net margin 19.6% (+162.1% vs. industry 7.5%), and ROE 21.3% — all achieved with minimal leverage (D/E 0.43x vs. industry 7.61x), confirming a structurally superior, durable competitive moat. Main concern: Valuation-growth mismatch has WORSENED AGAIN: PEG ratio deteriorated from 2.40 to 2.51 (+4.6%) as the stock rose another 4.8% to $155.40 while forward EPS growth remained unchanged at 9.0-9.4% — analyst consensus target of $160.17 now implies only 3.1% upside (down from 8.1% two weeks ago), offering virtually zero margin of safety and making the risk/reward at current prices deeply unattractive.
Investment Summary
Agilent Technologies (A) is a high-quality medical diagnostics and research business trading at a significant valuation premium that has WORSENED over the past two weeks. The stock has risen another 4.8% from $148.24 to $155.40 while the analyst consensus target remains unchanged at $160.17 — shrinking the upside to just 3.1% (down from 8.1% two weeks ago). The PEG ratio has deteriorated further from 2.40 to 2.51, now 67% above the 1.5x threshold I consider the upper bound for quality compounders. The P/E of 31.21x is deeply inconsistent with 5-year forward EPS growth of only 9.37% — a growth rate that is 56% below the industry average of 21.34%. The business itself is genuinely excellent: gross margin of 52.8% (vs. industry 48.1%), operating margin of 23.7% (vs. industry 11.5% — more than double peers), net margin of 19.6% (vs. industry 7.5% — 2.6x peers), ROE of 21.3% (vs. industry 18.4%), D/E of 0.43x (vs. industry 7.61x — 94% less leverage), and $930.6M in FCF. News is genuinely positive: FDA approval for PD-L1 IHC 28-8 pharmDx in esophageal cancer, EU approval for PD-L1 IHC 22C3 pharmDx in ovarian cancer, AI biopharma expansion, and HALO X-ray investment. However, none of these catalysts are sufficient to re-rate a 9% grower to justify a 31x P/E. This is a wonderful business at the wrong price — and the price has moved further in the wrong direction.
Key Strengths
- Profitability fortress with operating margin 23.7% (+105.6% vs. industry 11.5%), net margin 19.6% (+162.1% vs. industry 7.5%), and ROE 21.3% — all achieved with minimal leverage (D/E 0.43x vs. industry 7.61x), confirming a structurally superior, durable competitive moat
- Balance sheet fortress: $1.81B cash, $930.6M FCF, and D/E of 0.43x vs. industry average of 7.61x (94% less leverage than peers) provides exceptional resilience, strategic optionality, and insulation from refinancing risk that threatens heavily leveraged competitors
- Positive regulatory and product momentum: FDA approval for PD-L1 IHC 28-8 pharmDx in esophageal squamous cell carcinoma (expanding KEYTRUDA companion diagnostic reach), EU approval for PD-L1 IHC 22C3 pharmDx in epithelial ovarian cancer, AI-enhanced biopharma tools expansion, and HALO X-ray investment create incremental revenue streams in high-barrier oncology diagnostics
Key Concerns
- Valuation-growth mismatch has WORSENED AGAIN: PEG ratio deteriorated from 2.40 to 2.51 (+4.6%) as the stock rose another 4.8% to $155.40 while forward EPS growth remained unchanged at 9.0-9.4% — analyst consensus target of $160.17 now implies only 3.1% upside (down from 8.1% two weeks ago), offering virtually zero margin of safety and making the risk/reward at current prices deeply unattractive
- Structural growth laggard in a high-growth sector: Forward 5-year EPS growth of 9.37% is 56.1% below the industry average of 21.34%, and revenue growth of 10.0% is 49.6% below the industry's 19.85% pace — this is a structural, not cyclical, deficit that limits multiple expansion and creates significant downside re-rating risk if market sentiment shifts toward growth or if the sector's faster-growing peers attract capital rotation
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Agilent's fundamentals present a classic 'quality trap' scenario. Profitability is exceptional: gross margin 52.8% (+9.8% vs. industry 48.1%), operating margin 23.7% (+105.6% vs. industry 11.5%), net margin 19.6% (+162.1% vs. industry 7.5%), ROE 21.3% (+16.2% vs. industry 18.4%). Financial health is solid: D/E 0.43x (vs. industry 7.61x — 94% below peers), cash $1.81B, FCF $930.6M. These metrics confirm a genuinely superior, durable business model. However, valuation is the critical problem: P/E of 31.21x against 5-year EPS growth of only 9.37% produces a PEG of 2.51 — more than 2.5x what I consider fair value (PEG 1.0) and 67% above the generous upper bound (PEG 1.5). A fair P/E for a 9.4% grower is 14-19x (applying PEG 1.5-2.0 with quality premium), implying fair value of approximately $90-$110 — 29-42% below current price. The analyst consensus target of $160.17 implies only 3.1% upside from $155.40, offering zero margin of safety. Growth is the structural weakness: forward 1-year EPS growth 8.98% (vs. industry 19.87% — 54.8% below peers), forward 5-year EPS growth 9.37% (vs. industry 21.34% — 56.1% below peers), revenue growth 10.0% (vs. industry 19.85% — 49.6% below peers). Price-to-Book of 6.16x is elevated. The convergence of revenue growth (~10%) and forward EPS growth (~9%) signals no meaningful operating leverage or margin expansion ahead.
News Sentiment
Agilent Technologies is quietly building a stronger position in one of medicine's most exciting frontiers — cancer diagnostics — and the company's recent regulatory wins are turning heads on Wall Street. The medical diagnostics giant just scored back-to-back approvals that could meaningfully expand its revenue base. The FDA greenlit Agilent's PD-L1 IHC 28-8 pharmDx test for esophageal squamous cell carcinoma, making it a companion diagnostic for Merck's blockbuster cancer drug KEYTRUDA (pembrolizumab) — one of the best-selling drugs in the world. Meanwhile, European regulators approved the company's PD-L1 IHC 22C3 pharmDx test for epithelial ovarian cancer, further cementing Agilent's role as a gatekeeper in precision oncology. Think of these tests as the 'keys' that unlock access to KEYTRUDA treatment — every new cancer indication approved means more patients need Agilent's diagnostic before they can receive therapy. Beyond diagnostics, Agilent is betting big on artificial intelligence to supercharge its biopharma tools business, announcing AI-driven workflow improvements that could help drug developers work faster and smarter. The company also deepened its investment in HALO X-ray Technologies, expanding its technology portfolio. And for lab scientists, Agilent added new inert size exclusion and PLRP-S columns to its Altura portfolio, broadening its product lineup for biopharma customers. The bottom line: Agilent is executing well on its strategy, but investors should note that the stock's 4.8% rise in the past week has outpaced the actual business improvements — leaving limited upside to the analyst target of $160.17.
Risk Assessment
PRIMARY RISK: Multiple compression. At P/E 31.21x with 9.37% forward EPS growth (PEG 2.51), any disappointment in earnings, guidance, or macro sentiment could trigger a rapid de-rating toward a more appropriate 20-22x P/E — implying 30-35% downside to $100-$110. SECONDARY RISK: Sector rotation away from quality/defensive names toward higher-growth peers (industry forward EPS growth 21.34% vs. Agilent's 9.37%) could accelerate multiple compression. TERTIARY RISK: The analyst consensus target of $160.17 is only 3.1% above current price — if analysts revise targets downward (possible given the stock has outrun fundamentals), the stock loses its technical support from consensus. MITIGATION: Agilent's $1.81B cash, $930.6M FCF, and D/E of 0.43x provide a genuine floor — this is not a distressed situation. The business will continue to compound at 9-10% annually. For existing holders, the HOLD recommendation is appropriate as the business quality justifies patience. For new buyers, the entry zone of $128-$135 (approximately 13-18% below current price) is where the risk/reward becomes attractive: at $131.50 midpoint, upside to $160.17 is 21.8% vs. downside to $122 stop of 7.2% — a 3.0:1 ratio.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is A a halal stock?
Yes, Agilent Technologies, Inc. (A) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for A?
Agilent Technologies, Inc. (A) has a Plutrex AI rating of 58.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is A a good investment?
According to Plutrex AI, A has a Hold rating (58.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in A?
US stocks like A can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in A?
Plutrex AI identifies the main risks for A by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.